Douglas Palmer

Douglas Palmer is a dedicated professional focused on developing and implementing innovative immunotherapies for metastatic cancer treatment.

With a background in Immunology and Biochemistry, Palmer has made significant contributions to the field by identifying and translating negative regulators of T cell immunity, particularly in the context of cancer.

His research led to the discovery of Cish as an internal checkpoint blockade molecule, with implications for enhancing tumor-specific T cell immunity against cancer.

Palmer's expertise extends to biochemistry, large dataset analysis, and unraveling molecular and gene regulatory networks crucial for T cell function.

He successfully translated his research into a clinical trial, demonstrating his ability to bridge basic science with clinical applications.

Having co-authored numerous manuscripts in prestigious scientific journals and holding multiple patents, Palmer's work has had a substantial impact in the field, evident from his high citation rates and H-index.

In his current role as the Executive Director of Immuno-Oncology Translational Medicine at AstraZeneca, Palmer continues to lead efforts in identifying new negative regulators of T cell tumor immunity to enhance clinical outcomes.

His previous positions at the National Cancer Institute reflect his expertise and leadership in research, mentoring, and team building.

Palmer's background, education, and track record of achievements highlight his exceptional skills in managing, mentoring, innovation, and translation in the field of immunotherapy.